Item 9 Labs Corp. (OTCPK: INLB)
Health Care · Pharmaceuticals · US
$0.00
— today · 0.0% 1Y
Item 9 Labs Corp. (OTCPK: INLB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $702.00 and employs 97 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.00.
Tweenvest scores Item 9 Labs Corp. across four factors: quality 34/100, value 49/100, growth 100/100. Its strongest factor is growth.
INLB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $702.00
- Revenue (TTM)
- $19.69M
- P/E
- —
- EPS
- -0.32
- Dividend yield
- —
- Beta (5Y)
- 0.15
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 701.81M
- Employees
- 97
- Next earnings
- —
About Item 9 Labs Corp.
Based in the United States, Item 9 Labs Corp. operates as a comprehensive cannabis company, encompassing both vertical integration in cannabis operations and the franchising of dispensaries. The firm produces a wide spectrum of cannabis and related goods, such as raw flower, various concentrates, distillates, and necessary hardware. These cannabis and derived technologies and products are then supplied to consumers in Arizona via licensed retail dispensaries. Complementing its production activities, the company also develops and offers medical and adult-use cannabis dispensary franchises under its distinct Unity Rd brand. The main office for Item 9 Labs Corp. is found in Phoenix, Arizona.
- Listed since
- Jan 25, 2012
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.